Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast CancerBoca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) -- INmune

INMB

Brandywine Realty Trust Sees FY22 FFO $1.36-$1.40

By Michael Horton

October 20, 5:21 PM

2022 Earnings and FFO Guidance Based on current plans and assumptions and subject to the risks and uncertainties more fully described in our Securities and Exchange Commission filings, we are continuing our 2022

BDN

What’s Going On With Alibaba Stock Friday?

By Anusuya Lahiri

December 1, 8:01 AM

Alibaba Group Holding Limited's (NYSE: BABA) business-to-business wholesale marketplace, Alibaba.com, is set to enhance its merchant services with a new artificial intelligence (AI) tool.

BABA

Raymond James Downgrades VMware to Market Perform

Related Posts

Credit Suisse Maintains Outperform on MetLife, Raises Price Target to $77

INmune Bio Inc. Presents Data On INB03’s Role As An Immune Check Point Modulator In The Treatment Of High-Risk Breast Cancer At AACR 2024

Brandywine Realty Trust Sees FY22 FFO $1.36-$1.40

What’s Going On With Alibaba Stock Friday?